Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of Apo A-I and HDL-cholesterol

Atherosclerosis

Volumn 127, Issue 2, 1996, Pages 255-262

  Kamboh, M Ilyas ^a   Aston, Christopher E ^a   Nestlerode, Cara M ^a   McAllister, Andrea E ^a   Hamman, Richard F ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

+83 bp; 75 bp; apolipoprotein A I; haplotypes; linkage disequilibrium; non smokers; US whites

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; APOLIPOPROTEIN A-I; ARTERIOSCLEROSIS; CHOLESTEROL, HDL; DNA PROBES; FEMALE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0030595991     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)05966-7     Document Type: Article

References (37)

1. [1] Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso Heart Study. High-density lipoproteins as a protective factor against coronary heart disease: a prospective case-control study. Lancet 1977;i:965-968.
2. [2] Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dauber JR. High density lipoproteins as a protective factor against coronary heart disease: The Framingham Heart Study. Am J Med 1977;62:707-714.
3. [3] Badimon JJ, Fuster V, Badimon L. Role of high density lipoproteins in the regression of atherosclerosis. Circulation 1992;(Suppl III):III86-III94.
4. [4] Norum RA, Lakier JB, Goldstein S et al. Familial deficiency of apolipoproteins AI and CIII and precocious coronary-artery disease. N Engl J Med 1982;306:1513-1519.
5. [5] Srinivasan SR, Berenson GS. Serum apolipoprotein A-I and B as markers of coronary artery disease risk in early life: the Bogalusa Heart Study. Clin Chem 1995;41:159-164.
6. [6] Pieters MN, Schouten D, van Berkel JJC. In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport. Biochim Biophys Acta 1994;1225:125-134.
7. [7] Quintao ECR. Is reverse cholesterol transport a misnomer for suggesting its role in the prevention of atheroma formation? Atherosclerosis 1995;116:1-14.
8. [8] Moll PP, Michels VV, Weidman WH, Kottke BA. Genetic determination of plasma apolipoprotein AI in a population-based sample. Am J Hum Genet 1989;44:124-139.
9. [9] Prenger VL, Beaty TH, Kwiterovich PO. Genetic determination of high-density lipoprotein-cholesterol and apolipoprotein A-I plasma levels in a family study of cardiac catheterization patients. Am J Hum Genet 1992;51:1047-1057.
10. [10] Hasstedt SJ, Albers JJ, Cheung MC et al. The inheritance of high density lipoprotein cholesterol and apolipoproteins A-I and A-II. Atherosclerosis 1984;51:21-29.
11. [11] Borecki IB, Rao DC, Third JLHC, Laskarzewski MM, Glueck CJ. A major gene for primary hypoalphalipoproteinemia. Am J Hum Genet 1986;38:373-381.
12. [12] Amos CI, Elston RC, Srinivasan SR et al. Linkage and segregation analyses of apolipoproteins A1 and B, and lipoprotein cholesterol levels in a large pedigree with excess coronary heart disease: the Bogalusa Heart Study. Genet Epidemiol 1987;4:115-128.
13. [13] Assmann G, von Eckardstein A, Funke H. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation 1993;87(Suppl III):III28-III34.
14. [14] Jeenah M, Kessling A, Miller N, Humphries SE. G to A substitution in the promoter region of the apolipoprotein A-I gene is associated with elevated serum apolipoprotein A-I and high density lipoprotein cholesterol concentrations. Mol Biol Med 1990;7:233-241.
15. [15] Paul-Hayase F, Rossenneu M, Robinson D, Van Bervliet J, Deslypere JP, Humphries SE. Polymorphisms in the apolipoprotein (apo) A-I-C-III-A-IV gene cluster: detection of genetic variation determining plasma apo A-I, apo C-III and apo A-IV concentrations. Hum Genet 1992;88:439-446.
16. [16] Sigurdsson Jr. G, Gudnason V, Sigurdsson G, Humphries SE. Interaction between a polymorphism of the apo A-I promoter region and smoking determines plasma levels of HDL and apo A-I. Arterioscler Thromb 1992;12:1017-1022.
17. [17] Xu C-F, Angelico F, Del Ben M, Humphries SE. Role of genetic variation at the apo A-I-C-III-A-IV gene cluster in determining plasma apo A-I levels in boys and girls. Genet Epidemiol 1993;10:113-122.
18. [18] Talmud PJ, Ye S, Humphries SE, EARS Group. Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: The European Atherosclerosis Research Study. Genet Epidemiol 1994;11:265-280.
19. [19] Saha N, Tay JSH, Low PS, Humphries SE. Guanidine to adenine (G/A) substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI levels in Chinese non-smokers. Genet Epidemiol 1994;11:255-264.
20. [20] Minnich A, DeLangavant G, Lavigne J, Roederer G, Lussier-Cacan S, Davignon J. G → A substitution at position - 75 of the apolipoprotein A-I gene promoter. Evidence against a direct effect on HDL cholesterol levels. Arterioscler Thromb Vas Biol 1995;15:1740-1745.
21. [21] Smith JD, Brinton EA, Breslow JL. Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in intro. J Clin Invest 1992;89:1796-1800.
22. [22] Needham EWS, Mattu RK, Rees A, Stocks J, Galton DJ. A polymorphism in the human apolipoprotein AI promoter region: a study in hypertriglyceridaemic patients. Hum Hered 1994;44:94-99.
23. [23] Barre DE, Guerra R, Vertraete R, Wang Z, Grundy SM, Cohen JC. Genetic analysis of a polymorphism in the human apolipoprotein A-I gene promoter: effect on plasma HLD-cholesterol levels. J Lipid Res 1994;35:1292-1296.
24. [24] Wang XL, Badenhop R, Humphrey K, Wilcken DEL. C to T and G to A transitions are responsible for loss of a Mspl restriction site in the 5′-region of the human apolipoprotein AI gene. Hum Genet 1994;95:473-475.
25. [25] Hamman RF, Marshall JA, Baxter J et al. Methods and prevalence of non-insulin-dependent diabetes mellitus in a biethnic Colorado population: The San Luis Valley Diabetes Study. Am J Epidemiol 1989;129:295-311.
26. [26] Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia wp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem 1973;19:1350-1356.
27. [27] Warnick GR, Benderson JM, Albers JJ. Quantitation of high-density-lipoprotein subclasses after separation by dextran sulfate and magnesium precipitation. Clin Chem 1982;28:1574.
28. [28] Stavropolous WS, Crouch RD. A new colorimetric procedure for the determination of serum triglycerides. Clin Chem 1974;20:957.
29. [29] Kamboh MI, Hamman RF, Ferrell RE. Two common polymorphisms in the APOA-IV coding gene: their evolution and linkage disequilibrium. Genet Epidemiol 1992;9:305-315.
30. [30] Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika 1965;52:591-611.
31. [31] Templeton AR. The general relationship between average effect and average excess. Genet Res Comb 1987;49:69-70.
32. [32] Kamboh MI, Aston CE, Hamman RF. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis 1995;112:145-159.
33. [33] Boerwinkle E, Sing CF. Bias of the contribution of single locus effects to the variance of quantitative trait. Am J Hum Genet 1986;39:137-144.
34. [34] Jeenah MS, Wells C. Functional significance of a point mutation in the apo A-I promoter. Circulation 1992;86(Suppl):I-279 (Abstract).
35. [35] Tuteja R, Tuteja N, Melo C, Casari G, Baralle FE. Transcription efficiency of human apolipoprotein A-I promoter varies with naturally occurring A to G transition. FEBS Lett 1992;304:98-101.
36. [36] Shemer R, Walsh A, Eisenberg S, Breslow JL, Razin A. Tissue-specific methylation patterns and expression of the human apolipoprotein AI gene. J Biol Chem 1990;265:1010-1015.
37. [37] Wang XL, Badenhop R, Humphrey KE, Wilcken DEL. New Mspl polymorphism at + 83 bp of the human apolipoprotein AI gene: association with increased circulating high density lipoprotein cholesterol levels. Genet Epidemiol 1996;13:1-10.